A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 220 (final count)
- Started
- Jun 24, 2019
- Main results expected
- May 2026
- Fully finished
- May 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Dose-limiting toxicities (DLT)
Measured over: Day 21
Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
Measured over: Up to 3 Years
Maximum Observed Plasma Concentration of TNB-383B (Cmax)
Measured over: Week 12
Time to Cmax of TNB-383B (Tmax)
Measured over: Week 12
Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUClast)
Measured over: Week 12
Clearance (CL) of TNB-383B
Measured over: Week 12
Terminal Phase Elimination Rate Constant (Beta) of TNB-383B
Measured over: Week 12
Terminal Half-Life (t1/2) of TNB-383B
Measured over: Week 12
Number of Participants with of Anti-drug Antibody (ADA)
Measured over: Up to Month 48
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03933735 · record last updated 2026-02-06 · checked 2026-11-09 15:47 UTC